Go Pro
→ Your book attached (From Profits Run) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
$24.77
-2.1%		$31.09
$4.71
▼
$37.48
$993.22M1.32598,154 shs660,689 shs
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
$25.16
-0.5%		$25.62
$19.30
▼
$31.77
$3.16B1.573.47 million shs1.78 million shs
Organon & Co. stock logo
OGN
Organon & Co.
$13.74
+0.2%		$13.69
$5.69
▼
$13.78
$3.60B1.552.29 million shs1.92 million shs
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
$73.00
-3.3%		$73.07
$53.89
▼
$91.53
$3.20B0.44778,393 shs805,651 shs
The 10 Best High-Yield Dividend Stocks for 2026 Cover
The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
-1.76%-6.94%-32.59%-0.03%+505.67%
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
-0.51%-6.54%+5.49%-2.52%+27.33%
Organon & Co. stock logo
OGN
Organon & Co.
+0.09%+0.01%-0.28%+1.27%+24.94%
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
-3.26%-3.55%-11.79%+11.55%+27.31%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
$24.77
-2.1%		$31.09
$4.71
▼
$37.48
$993.22M1.32598,154 shs660,689 shs
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
$25.16
-0.5%		$25.62
$19.30
▼
$31.77
$3.16B1.573.47 million shs1.78 million shs
Organon & Co. stock logo
OGN
Organon & Co.
$13.74
+0.2%		$13.69
$5.69
▼
$13.78
$3.60B1.552.29 million shs1.92 million shs
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
$73.00
-3.3%		$73.07
$53.89
▼
$91.53
$3.20B0.44778,393 shs805,651 shs
The 10 Best High-Yield Dividend Stocks for 2026 Cover
The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
-1.76%-6.94%-32.59%-0.03%+505.67%
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
-0.51%-6.54%+5.49%-2.52%+27.33%
Organon & Co. stock logo
OGN
Organon & Co.
+0.09%+0.01%-0.28%+1.27%+24.94%
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
-3.26%-3.55%-11.79%+11.55%+27.31%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
2.64
Moderate Buy$37.2550.37% Upside
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
2.67
Moderate Buy$35.5741.38% Upside
Organon & Co. stock logo
OGN
Organon & Co.
1.71
Reduce$11.40-17.01% Downside
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
2.80
Moderate Buy$100.8638.16% Upside

Current Analyst Ratings Breakdown

Latest ANRO, OGN, TARS, and ARQT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/24/2026
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold (C-) ➝ Hold (C)
9/24/2026
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$116.00
9/24/2026
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$116.00
9/16/2026
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOverweight$110.00
9/16/2026
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight$110.00
9/8/2026
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold (C) ➝ Hold (C-)
9/8/2026
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$88.00 ➝ $105.00
9/4/2026
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$88.00 ➝ $105.00
8/20/2026
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold (C-) ➝ Hold (C)
8/20/2026
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong Sell ➝ Hold
8/17/2026
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$50.00 ➝ $55.00
(Data available from 10/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
N/AN/AN/AN/A$4.87 per shareN/A
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
$463.98M6.82N/AN/A$1.55 per share16.23
Organon & Co. stock logo
OGN
Organon & Co.
$6.13B0.59$5.80 per share2.37$2.89 per share4.75
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
$606.33M5.28N/AN/A$8.09 per share9.02
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
-$63.24M-$2.42N/AN/AN/AN/A-46.46%-39.09%11/11/2026 (Estimated)
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
-$16.14M$0.21119.8222.07N/A6.15%15.05%6.51%10/27/2026 (Estimated)
Organon & Co. stock logo
OGN
Organon & Co.
$187M$0.7717.843.991.273.41%88.97%6.03%11/9/2026 (Estimated)
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
-$66.42M-$1.09N/A121.67N/A-7.67%-13.53%-8.12%11/3/2026 (Estimated)

Latest ANRO, OGN, TARS, and ARQT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
10/27/2026Q3 2026
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
$0.1871N/AN/AN/A$141.69 millionN/A
8/12/2026Q2 2026
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
-$0.7345-$0.65+$0.0845-$0.65N/AN/A
8/6/2026Q2 2026
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
-$0.1918-$0.43-$0.2382-$0.43$169.65 million$173.91 million
8/5/2026Q2 2026
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
$0.0551$0.11+$0.0549$0.11$118.85 million$129.86 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
N/AN/AN/AN/AN/A
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
N/AN/AN/AN/AN/A
Organon & Co. stock logo
OGN
Organon & Co.
$0.080.58%N/A10.39%N/A
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
N/AN/AN/AN/AN/A

Latest ANRO, OGN, TARS, and ARQT Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/31/2026
Organon & Co. stock logo
OGN
Organon & Co.
quarterly$0.020.58%8/14/20268/14/20269/10/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
0.07
14.85
14.85
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
0.46
2.92
2.67
Organon & Co. stock logo
OGN
Organon & Co.
8.43
1.95
1.44
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
0.21
3.20
3.17

Institutional Ownership

CompanyInstitutional Ownership
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
N/A
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
N/A
Organon & Co. stock logo
OGN
Organon & Co.
77.43%
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
90.01%

Insider Ownership

CompanyInsider Ownership
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
11.25%
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
9.40%
Organon & Co. stock logo
OGN
Organon & Co.
1.62%
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
9.64%
CompanyEmployeesShares OutstandingFree FloatOptionable
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
6839.24 million34.83 millionN/A
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
354125.69 million113.88 millionOptionable
Organon & Co. stock logo
OGN
Organon & Co.
10,000262.61 million258.36 millionNot Optionable
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
37043.88 million39.65 millionOptionable

Recent News About These Companies

Tarsus to Present 11 Abstracts at Anaheim Eye Meeting
September 29, 2026  |  ocbj.comO
Tarsus Plans to Present 11 Abstracts Highlighting New Insights in Demodex Blepharitis, Ocular Rosacea and the Real-World Impact of XDEMVY at the American Academy of Optometry ...
September 29, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/tarsus-plans-to-present-11-abstracts-highlighting-new-insights-in-demodex-blepharitis-ocular-rosacea-and-the-real-world-impact-of-xdemvy-at-the-american-academy-of-optometry-2026-annual-meeting-1036581332
Tarsus Plans to Present 11 Abstracts Highlighting New Insights in Demodex Blepharitis, Ocular Rosacea and the Real-World Impact of XDEMVY at the American Academy of Optometry 2026 Annual Meeting
September 29, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/29/3370836/0/en/tarsus-plans-to-present-11-abstracts-highlighting-new-insights-in-demodex-blepharitis-ocular-rosacea-and-the-real-world-impact-of-xdemvy-at-the-american-academy-of-optometry-2026-a.html
Tarsus Pharmaceuticals (NASDAQ:TARS) Upgraded to "Strong-Buy" at The Goldman Sachs Group
September 26, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-tarsus-pharmaceuticals-nasdaq-tars-upgraded-to-strong-buy-at-the-goldman-sachs-group-2026-09-26/
Tarsus Pharmaceuticals (TARS) Receives a Buy from Goldman Sachs
September 25, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/TARS/pressreleases/4794598/tarsus-pharmaceuticals-tars-receives-a-buy-from-goldman-sachs/
Reviewing Aurora Cannabis (NASDAQ:ACB) and Tarsus Pharmaceuticals (NASDAQ:TARS)
September 24, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31044383
Bank of America Corp DE Acquires New Stake in Tarsus Pharmaceuticals, Inc. $TARS
September 20, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bank-of-america-corp-de-acquires-new-stake-in-tarsus-pharmaceuticals-inc-tars-2026-09-20/
Tarsus Pharmaceuticals Insider Sold Shares Worth $979,744, According to a Recent SEC Filing
September 19, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/tarsus-pharmaceuticals-insider-sold-shares-203447683.html
Pyott David E I Executes Options in Tarsus Pharmaceuticals, Retains 9,575 Shares
September 18, 2026  |  kalkinemedia.comK
Tarsus Pharmaceuticals (NASDAQ:TARS) Upgraded by Barclays to Strong-Buy Rating
September 18, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-tarsus-pharmaceuticals-nasdaq-tars-upgraded-by-barclays-to-strong-buy-rating-2026-09-18/
William Phd Link Sells 12,500 Shares of Tarsus Pharmaceuticals (NASDAQ:TARS) Stock
September 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-william-phd-link-sells-12500-shares-of-tarsus-pharmaceuticals-nasdaq-tars-stock-2026-09-17/
Hsbc Holdings PLC Grows Stake in Tarsus Pharmaceuticals, Inc. $TARS
September 12, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-hsbc-holdings-plc-grows-stake-in-tarsus-pharmaceuticals-inc-tars-2026-09-12/
Wellington Management Group LLP Purchases 24,117 Shares of Tarsus Pharmaceuticals, Inc. $TARS
September 11, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-wellington-management-group-llp-purchases-24117-shares-of-tarsus-pharmaceuticals-inc-tars-2026-09-11/
Insider Selling: Tarsus Pharmaceuticals (NASDAQ:TARS) CEO Sells $905,600.00 in Stock
September 10, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-tars-insider-buying-and-selling-2026-09-10/
Squarepoint Ops LLC Buys 54,791 Shares of Tarsus Pharmaceuticals, Inc. $TARS
September 10, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-squarepoint-ops-llc-buys-54791-shares-of-tarsus-pharmaceuticals-inc-tars-2026-09-10/
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives Average Rating of "Moderate Buy" from Analysts
September 10, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-tarsus-pharmaceuticals-inc-nasdaq-tars-receives-average-rating-of-moderate-buy-from-analysts-2026-09-10/
Bobak Azamian Sells 10,000 Shares of Tarsus Pharmaceuticals (NASDAQ:TARS) Stock
September 9, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-bobak-azamian-sells-10000-shares-of-tarsus-pharmaceuticals-nasdaq-tars-stock-2026-09-09/
Insider Selling: Tarsus Pharmaceuticals (NASDAQ:TARS) Insider Sells $942,637.50 in Stock
September 9, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-insider-selling-tarsus-pharmaceuticals-nasdaq-tars-insider-sells-94263750-in-stock-2026-09-09/
Jefferies Financial Group Increases Tarsus Pharmaceuticals (NASDAQ:TARS) Price Target to $105.00
September 8, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-jefferies-financial-group-increases-tarsus-pharmaceuticals-nasdaq-tars-price-target-to-10500-2026-09-08/
Tarsus Finalizes Alkeus Acquisition, Expanding Eyecare Pipeline
September 8, 2026  |  visionmonday.comV
Legal & General Group Plc Makes New $1.75 Million Investment in Tarsus Pharmaceuticals, Inc. $TARS
September 7, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-legal-general-group-plc-makes-new-175-million-investment-in-tarsus-pharmaceuticals-inc-tars-2026-09-07/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Micron, Coherent and Tower Semiconductor: 3 Stocks Built on AI's Bottlenecks
NVIDIA Just Named AI's Next Bottleneck—And These 3 Stocks Sit Right In It
By Bridget Bennett | September 20, 2026
A Tesla concept vehicle with illuminated front light bar drives on a road against a city skyline at dusk.
Tesla’s Robotaxi Launch Wasn’t the Moment Investors Expected
By Sam Quirke | September 8, 2026
Data center hallway with rows of server racks and cables, plus a monitoring room with computer screens in the background.
AI Token Costs Are Changing the Hardware vs. Software Debate
By Jeffrey Neal Johnson | September 6, 2026
Aerial twilight view of multiple rockets on launch pads at Kennedy Space Center, with support towers and ground vehicles.
3 Space Stocks to Watch as SpaceX Reshapes the Launch Market
By Jeffrey Neal Johnson | September 25, 2026
Illustration of a SpaceX rocket launching above Earth's atmosphere with the SpaceX logo displayed against a starry sky.
Why SpaceX Investors Should Look Past Starship’s Fiery Splashdown
By Jeffrey Neal Johnson | September 29, 2026
Alto Neuroscience stock logo

Alto Neuroscience NYSE:ANRO

$24.77 -0.54 (-2.13%)
Closing price 10/2/2026 03:59 PM Eastern
Extended Trading
$24.86 +0.09 (+0.36%)
As of 10/2/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder. The company develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with MDD; ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor which is in phase 1 clinical trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist which is in phase 1 clinical trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor which is in phase 1 clinical trial for the treatment of MDD. In addition, it develops novel pharmacodynamically synergistic combination and biomarker platform that collects patient-specific data to identify biomarker-characterized patient. The company was incorporated in 2019 and is headquartered in Los Altos, California.

Arcutis Biotherapeutics stock logo

Arcutis Biotherapeutics NASDAQ:ARQT

$25.16 -0.13 (-0.51%)
Closing price 10/2/2026 04:00 PM Eastern
Extended Trading
$25.16 0.00 (-0.02%)
As of 10/2/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Organon & Co. stock logo

Organon & Co. NYSE:OGN

$13.74 +0.03 (+0.20%)
Closing price 10/2/2026 03:59 PM Eastern
Extended Trading
$13.65 -0.08 (-0.60%)
As of 10/2/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

Tarsus Pharmaceuticals stock logo

Tarsus Pharmaceuticals NASDAQ:TARS

$73.00 -2.46 (-3.26%)
Closing price 10/2/2026 04:00 PM Eastern
Extended Trading
$73.08 +0.08 (+0.12%)
As of 10/2/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas